Johnson & Johnson Reveals P-III (ICONIC-LEAD) Trial Data of Icotrokinra for Plaque Psoriasis
Shots:
- J&J has reported subgroup analysis from P-III (ICONIC-LEAD) trial assessing icotrokinra (QD, PO; n=456) vs PBO (n=228) in 684 adolescents & adults with mod. to sev. plaque PsO
- At Wk. 16, 84.1% adolescent achieved IGA 0/1 vs 27.3%, & 70.5% vs 13.6% reached PASI 90. By Wk. 24, 86.4% achieved IGA 0/1, 88.6% reached PASI 90, plus 75% had completely clear skin (IGA 0), with 63.6% achieving PASI 100; data was presented at WCPD 2025
- Icotrokinra (JNJ-2113) is being evaluated in ICONIC Program: ICONIC-TOTAL (vs PBO) for PsO, ICONIC-ADVANCE 1 & 2 (vs PBO & Sotyktu) & ICONIC-ASCEND (vs PBO & Stelara) for mod. to sev. PsO, plus ICONIC-PsA 1 & 2 (vs PBO) for active PsA
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Reports P-III (Vivacity-MG3) Trial Data of Nipocalimab for Generalized Myasthenia Gravis
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
